血脂异常与结直肠锯齿状病变、结直肠癌相关性研究进展

doi:10.12114/j.issn.1007-9572.2023.0244

中国全科医学 ›› 2024, Vol. 27 ›› Issue (12): 1424-1430.DOI: 10.12114/j.issn.1007-9572.2023.0244

所属专题：肿瘤最新文章合辑；消化系统疾病最新文章合辑

血脂异常与结直肠锯齿状病变、结直肠癌相关性研究进展

冉东升¹, 逯艳艳², 辛春玲¹, 马颖才²^,^*()

1．810000　青海省西宁市，青海大学研究生院
2．810000　青海省西宁市，青海省人民医院消化内科

收稿日期:2023-04-10 修回日期:2023-06-05 出版日期:2024-04-20 发布日期:2024-01-23
通讯作者: 马颖才
作者贡献：冉东升、逯艳艳负责文章选题和构思、文献检索、数据资料整理；冉东升负责论文撰写；逯艳艳、辛春玲进行文章修订；马颖才负责文章的质量控制及审校，对文章整体负责；所有作者确认了论文的最终稿。
基金资助:
青海省卫生健康系统指导性计划课题(2022-wjzdx-11)

Research Progress on the Correlation of Dyslipidemia with Colorectal Serrated Lesions and Colorectal Cancer

RAN Dongsheng¹, LU Yanyan², XIN Chunling¹, MA Yingcai²^,^*()

1. Graduate School of Qinghai University, Xining 810000, China
2. Department of Gastroenterology, Qinghai Provincial People's Hospital, Xining 810000, China

Received:2023-04-10 Revised:2023-06-05 Published:2024-04-20 Online:2024-01-23
Contact: MA Yingcai

摘要/Abstract

摘要： 血脂水平异常可能与结直肠肿瘤的发生、发展有关。目前，众多研究证实血脂异常增加了患结直肠腺瘤的风险，然而血脂异常与结直肠锯齿状病变、结直肠癌的关联仍存在争议，并且国内相关综述较少。本文全面探讨了血脂异常与结直肠锯齿状病变、结直肠癌相关性，分析了可能造成争议的原因，指出后续的研究方向，并讨论了血脂异常在结直肠肿瘤发生、发展中发挥的作用，提示血脂异常与结直肠锯齿状病变、结直肠癌有关。血脂异常可能是通过胰岛素抵抗、炎性因子、氧化应激、高脂饮食、免疫抑制等多种机制相互作用参与了结直肠肿瘤的发生、发展。结直肠癌发病率逐年上升，而其具有较缓慢的自然病程和较明确的癌前病变，因此明确血脂指标与结直肠肿瘤的相关性，便于早期预防和有针对性的筛查，为未来制订有针对性的预防结直肠癌策略提供参考。

关键词: 高脂血症, 血脂异常, 结直肠肿瘤, 结直肠锯齿状病变, 结直肠癌, 综述

Abstract:

Dyslipidemia may be related to the occurrence and development of colorectal tumors. Numerous studies have confirmed that dyslipidemia increases the risk of colorectal adenomas at present; however, the association of dyslipidemia with colorectal serrated lesions and colorectal cancer is still controversial, and there are few relevant reviews in China. This article comprehensively explores the correlation of dyslipidemia with colorectal serrated lesions and colorectal cancer, analyzes the possible causes of controversy, identifies the directions of subsequent researches, and discusses the role of dyslipidemia in the occurrence and progression of colorectal tumors. This article indicates that dyslipidemia is associated with colorectal serrated lesions and colorectal cancer. Dyslipidemia may be involved in the development of colorectal tumors through the interaction of multiple mechanisms such as insulin resistance, inflammatory factors, oxidative stress, high-fat diet and immunosuppression. The incidence of colorectal cancer is increasing yearly with a relatively slower natural course and more definite precancerous lesions. Therefore, the clarification of correlation between lipid indexes and colorectal tumors can facilitate early prevention and targeted screening of colorectal tumors and provide a reference for formulating targeted prevention strategies for colorectal cancer.

Key words: Hyperlipidemias, Dyslipidemias, Colorectal neoplasms, Colorectal serrated lesions, Colorectal cancer, Review

冉东升,逯艳艳,辛春玲,等. 血脂异常与结直肠锯齿状病变、结直肠癌相关性研究进展[J]. 中国全科医学, 2024, 27(12): 1424-1430. DOI: 10.12114/j.issn.1007-9572.2023.0244.
RAN Dongsheng,LU Yanyan,XIN Chunling, et al. Research Progress on the Correlation of Dyslipidemia with Colorectal Serrated Lesions and Colorectal Cancer[J]. Chinese General Practice, 2024, 27(12): 1424-1430. DOI: 10.12114/j.issn.1007-9572.2023.0244.

参考文献 62

[1]	SUNG H, FERLAY J, SIEGEL R L，et al. Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin，2021,71(3):209-249. DOI：10.3322/caac.21660.
[2]	ZHANG L, CAO F, ZHANG G Y，et al. Trends in and predictions of colorectal cancer incidence and mortality in China from 1990 to 2025[J]. Front Oncol，2019,9:98. DOI：10.3389/fonc.2019.00098.
[3]	XIA C F, DONG X S, LI H，et al. Cancer statistics in China and United States，2022：profiles，trends，and determinants[J]. Chin Med J （Engl），2022,135(5):584-590. DOI：10.1097/CM9.0000000000002108.
[4]	MONACHESE M, MANKANEY G, EL-KHIDER F，et al. Association between baseline hyperplastic polyps and metachronous serrated lesions[J]. Gastrointest Endosc，2021,93(6):1401-1407.e1. DOI：10.1016/j.gie.2020.11.028.
[5]	SANO W, HIRATA D, TERAMOTO A，et al. Serrated polyps of the colon and rectum：remove or not?[J]. World J Gastroenterol，2020,26(19):2276-2285. DOI：10.3748/wjg.v26.i19.2276.
[6]	CROCKETT S D, NAGTEGAAL I D. Terminology，molecular features，epidemiology，and management of serrated colorectal neoplasia[J]. Gastroenterology，2019,157(4):949-966.e4. DOI：10.1053/j.gastro.2019.06.041.
[7]	SONG N, LIU F, HAN M，et al. Prevalence of overweight and obesity and associated risk factors among adult residents of northwest China：a cross-sectional study[J]. BMJ Open，2019,9(9):e028131. DOI：10.1136/bmjopen-2018-028131.
[8]	PASSARELLI M N, NEWCOMB P A. Blood lipid concentrations and colorectal adenomas：a systematic review and meta-analysis of colonoscopy studies in Asia，2000-2014[J]. Am J Epidemiol，2016,183(8):691-700. DOI：10.1093/aje/kwv294.
[9]	KIM J, LEE J Y, HWANG S W，et al. Risk factors of traditional serrated adenoma and clinicopathologic characteristics of synchronous conventional adenoma[J]. Gastrointest Endosc，2019,90(4):636-646.e9. DOI：10.1016/j.gie.2019.04.241.
[10]	MACARIE M, BATAGA S, MOCAN S，et al. Correlation of metabolic risk factors with sessile serrated lesions[J]. J Gastrointestin Liver Dis，2020,29(2):175-179. DOI：10.15403/jgld-507.
[11]	肖强，杨善峰，李祥. 结直肠腺瘤性息肉患者血脂水平的影响因素及相关性研究[J]. 安徽医学，2018,39(6):718-721. DOI：10.3969/j.issn.1000-0399.2018.06.024.
[12]	金辉，盛玲玲，杨再兴，等. 不同结直肠息肉类型患者血脂水平的临床分析[J]. 全科医学临床与教育，2021,19(3):221-223,235. DOI：10.13558/j.cnki.issn1672-3686.2021.003.008.
[13]	HANG D, HE X S, KVÆRNER A S，et al. Plasma biomarkers of insulin and the insulin-like growth factor axis，and risk of colorectal adenoma and serrated polyp[J]. JNCI Cancer Spectr，2019,3(3):pkz056. DOI：10.1093/jncics/pkz056.
[14]	DE PALMA F D E, D'ARGENIO V, POL J，et al. The molecular hallmarks of the serrated pathway in colorectal cancer[J]. Cancers（Basel），2019,11(7):1017. DOI：10.3390/cancers11071017.
[15]	TROVATO A, TURSHUDZHYAN A, TADROS M. Serrated lesions：a challenging enemy[J]. World J Gastroenterol，2021,27(34):5625-5629. DOI：10.3748/wjg.v27.i34.5625.
[16]	朱静兰. 619例患者的血脂与结直肠息肉发生发展的关系分析[D]. 衡阳：南华大学，2017.
[17]	FLISS-ISAKOV N, ZELBER-SAGI S, WEBB M，et al. Distinct metabolic profiles are associated with colorectal adenomas and serrated polyps[J]. Obesity （Silver Spring），2017,25(Suppl 2):S72-80. DOI：10.1002/oby.22001.
[18]	PYO J H, HA S Y, HONG S N，et al. Identification of risk factors for sessile and traditional serrated adenomas of the colon by using big data analysis[J]. J Gastroenterol Hepatol，2018,33(5):1039-1046. DOI：10.1111/jgh.14035.
[19]	TANG C T, LI J, YANG Z Z，et al. Different lipid metabolic profiles and their associated genes in sessile serrated adenoma or polyps compared to hyperplastic polyps[J]. Am J Cancer Res，2022,12(5):1982-1994.
[20]	XIE C X, WEN P W, SU J L，et al. Elevated serum triglyceride and low-density lipoprotein cholesterol promotes the formation of colorectal polyps[J]. BMC Gastroenterol，2019,19(1):195. DOI：10.1186/s12876-019-1115-9.
[21]	应斐，吕丽红，应丽丽，等. 结直肠息肉不同病理类型的危险因素分析[J]. 浙江医学，2019,41(6):579-582. DOI：10.12056/j.issn.1006-2785.2019.41.11.2017-1454.
[22]	潘程宇. 结直肠息肉与血脂水平的相关性研究[J]. 中国卫生标准管理，2019,10(23):16-18. DOI：10.3969/j.issn.1674-9316.2019.23.007.
[23]	武良琴，李小萍，何薇. 外周血血脂水平与结直肠息肉的相关性分析[J]. 医学综述，2021,27(14):2904-2908. DOI：10.3969/j.issn.1006-2084.2021.14.036.
[24]	WANG X R, ZOU Y B, ZHANG R X，et al. The relationship between serum lipid levels and colorectal serrated lesions：a systematic review and meta-analysis[J]. Front Physiol，2022,13:984586. DOI：10.3389/fphys.2022.984586.
[25]	CHUNG Y W, HAN D S, PARK Y K，et al. Association of obesity，serum glucose and lipids with the risk of advanced colorectal adenoma and cancer：a case-control study in Korea[J]. Dig Liver Dis，2006,38(9):668-672. DOI：10.1016/j.dld.2006.05.014.
[26]	董大庆，李炳庆，何培元. 血脂在结直肠癌中应用价值的研究[J]. 世界最新医学信息文摘，2019,19(6):199-201. DOI：10.3969/j.issn.1671-3141.2019.06.101.
[27]	何爽. 血脂指标及多项血清肿瘤标志物对结直肠癌的诊断价值[J]. 系统医学，2022,7(12):38-41. DOI：10.19368/j.cnki.2096-1782.2022.12.038.
[28]	TIAN Y, WANG K M, LI J，et al. The association between serum lipids and colorectal neoplasm：a systemic review and meta-analysis[J]. Public Health Nutr，2015,18(18):3355-3370. DOI：10.1017/S1368980015000646.
[29]	周璀，梁钰，侯利丹，等. 结直肠息肉与血脂异常关系的回顾性研究[J]. 国际消化病杂志，2020,40(5):314-318. DOI：10.3969/j.issn.1673-534X.2020.05.007.
[30]	YAO X, TIAN Z. Dyslipidemia and colorectal cancer risk：a meta-analysis of prospective studies[J]. Cancer Causes Control，2015,26(2):257-268. DOI：10.1007/s10552-014-0507-y.
[31]	YANG Z P, TANG H Z, LU S，et al. Relationship between serum lipid level and colorectal cancer：a systemic review and meta-analysis[J]. BMJ Open，2022,12(6):e052373. DOI：10.1136/bmjopen-2021-052373.
[32]	YUAN F C, WEN W Q, JIA G C，et al. Serum lipid profiles and cholesterol-lowering medication use in relation to subsequent risk of colorectal cancer in the UK biobank cohort[J]. Cancer Epidemiol Biomarkers Prev，2023,32(4):524-530. DOI：10.1158/1055-9965.EPI-22-1170.
[33]	FANG Z, HE M M, SONG M Y. Serum lipid profiles and risk of colorectal cancer：a prospective cohort study in the UK Biobank[J]. Br J Cancer，2021,124(3):663-670. DOI：10.1038/s41416-020-01143-6.
[34]	CHAPMAN T P, GOMES C F, LOUIS E，et al. De-escalation of immunomodulator and biological therapy in inflammatory bowel disease[J]. Lancet Gastroenterol Hepatol，2020,5(1):63-79. DOI：10.1016/S2468-1253(19)30186-4.
[35]	IBÁÑEZ-SANZ G, DÍEZ-VILLANUEVA A, RIERA-PONSATI M，et al. Mendelian randomization analysis rules out disylipidaemia as colorectal cancer cause[J]. Sci Rep，2019,9(1):13407. DOI：10.1038/s41598-019-49880-w.
[36]	毕崇尧，赫长胜，季志刚，等. 结直肠癌患者血浆胆固醇水平相关研究[J]. 结直肠肛门外科，2013,19(5):295-296. DOI：10.3969/j.issn.1009-6647.2006.01.008.
[37]	黄锐，刘超，张艳桥. 辛伐他汀用于结直肠癌治疗的系统综述[J]. 实用肿瘤学杂志，2021,35(4):365-369. DOI：10.11904/j.issn.1002-3070.2021.04.013.
[38]	郎吉萍，戴秋月，吕萍，等. 阿司匹林对结直肠癌化学预防作用的新进展[J]. 分子影像学杂志，2021,44(2):405-411. DOI：10.12122/j.issn.1674-4500.2021.02.38.
[39]	李玲，宋光耀. 健康体检者胰岛素抵抗与血脂异常的相关性及血脂最佳分界值的探讨[J]. 医学信息，2020,33(1):94-97. DOI：10.3969/j.issn.1006-1959.2020.01.028.
[40]	HENDERSON G C. Plasma free fatty acid concentration as a modifiable risk factor for metabolic disease[J]. Nutrients，2021,13(8):2590. DOI：10.3390/nu13082590.
[41]	LEROITH D, HOLLY J M P, FORBES B E. Insulin-like growth factors：ligands，binding proteins，and receptors[J]. Mol Metab，2021,52:101245. DOI：10.1016/j.molmet.2021.101245.
[42]	SHAO J Y, SHENG H M. Prostaglandin E2 induces the expression of IL-1α in colon cancer cells[J]. J Immunol，2007,178(7):4097-4103. DOI：10.4049/jimmunol.178.7.4097.
[43]	DE ARAÚJO W M, TANAKA M N, LIMA P H S，et al. TGF-β acts as a dual regulator of COX-2/PGE2 tumor promotion depending of its cross-interaction with H-Ras and Wnt/β-catenin pathways in colorectal cancer cells[J]. Cell Biol Int，2021,45(3):662-673. DOI：10.1002/cbin.11519.
[44]	HASHIMOTO T, OGAWA R, YOSHIDA H，et al. Acquisition of WNT pathway gene alterations coincides with the transition from precursor polyps to traditional serrated adenomas[J]. Am J Surg Pathol，2019,43(1):132-139. DOI：10.1097/PAS.0000000000001149.
[45]	周林香，沈磊. 结直肠无蒂锯齿状腺瘤的研究进展[J]. 中华消化内镜杂志，2021,38(12):1035-1040. DOI：10.3760/cma.j.cn321463-20200619-00349.
[46]	KASPRZAK A. Insulin-like growth factor 1 （IGF-1） signaling in glucose metabolism in colorectal cancer[J]. Int J Mol Sci，2021,22(12):6434. DOI：10.3390/ijms22126434.
[47]	KASPRZAK A. Autophagy and the insulin-like growth factor （IGF） system in colonic cells：implications for colorectal neoplasia[J]. Int J Mol Sci，2023,24(4):3665. DOI：10.3390/ijms24043665.
[48]	ROHR M W, NARASIMHULU C A, RUDESKI-ROHR T A，et al. Negative effects of a high-fat diet on intestinal permeability：a review[J]. Adv Nutr，2020,11(1):77-91. DOI：10.1093/advances/nmz061.
[49]	SHEN Y M, WANG C H, REN Y Z，et al. A comprehensive look at the role of hyperlipidemia in promoting colorectal cancer liver metastasis[J]. J Cancer，2018,9(16):2981-2986. DOI：10.7150/jca.25640.
[50]	LIU T, ZHANG Q S, SONG C H，et al. C-reactive protein trajectories and the risk of all cancer types：a prospective cohort study[J]. Int J Cancer，2022,151(2):297-307. DOI：10.1002/ijc.34012.
[51]	BOWIE R V, DONATELLO S, LYES C，et al. Lipid rafts are disrupted in mildly inflamed intestinal microenvironments without overt disruption of the epithelial barrier[J]. Am J Physiol Gastrointest Liver Physiol，2012,302(8):G781-793. DOI：10.1152/ajpgi.00002.2011.
[52]	ESTEVE E, RICART W, FERNÁNDEZ-REAL J M. Dyslipidemia and inflammation：an evolutionary conserved mechanism[J]. Clin Nutr，2005,24(1):16-31. DOI：10.1016/j.clnu.2004.08.004.
[53]	GONÇALVES A C. Oxidative stress and high-density lipoprotein cholesterol：cause or consequence?[J]. Revista Portuguesa De Cardiol，2022,41(10):841-842. DOI：10.1016/j.repc.2022.06.006.
[54]	MOHAMMAD S, THIEMERMANN C. Role of metabolic endotoxemia in systemic inflammation and potential interventions[J]. Front Immunol，2020,11:594150. DOI：10.3389/fimmu.2020.594150.
[55]	KING R J, SINGH P K, MEHLA K. The cholesterol pathway：impact on immunity and cancer[J]. Trends Immunol，2022,43(1):78-92. DOI：10.1016/j.it.2021.11.007.
[56]	BEYAZ S, MANA M D, ROPER J，et al. High-fat diet enhances stemness and tumorigenicity of intestinal progenitors[J]. Nature，2016,531(7592):53-58. DOI：10.1038/nature17173.
[57]	PENG X, HE Y E, HUANG J，et al. Metabolism of dendritic cells in tumor microenvironment：for immunotherapy[J]. Front Immunol，2021,12:613492. DOI：10.3389/fimmu.2021.613492.
[58]	WU H, HAN Y J, RODRIGUEZ SILLKE Y，et al. Lipid droplet-dependent fatty acid metabolism controls the immune suppressive phenotype of tumor-associated macrophages[J]. EMBO Mol Med，2019,11(11):e10698. DOI：10.15252/emmm.201910698.
[59]	LIU T C, KERN J T, JAIN U，et al. Western diet induces Paneth cell defects through microbiome alterations and farnesoid X receptor and type I interferon activation[J]. Cell Host Microbe，2021,29(6):988-1001.e6. DOI：10.1016/j.chom.2021.04.004.
[60]	TANG W S, ZHOU J Y, YANG W Q，et al. Aberrant cholesterol metabolic signaling impairs antitumor immunosurveillance through natural killer T cell dysfunction in obese liver[J]. Cell Mol Immunol，2022,19(7):834-847. DOI：10.1038/s41423-022-00872-3.
[61]	MA X Z, BI E G, LU Y，et al. Cholesterol induces CD₈⁺ T cell exhaustion in the tumor microenvironment[J]. Cell Metab，2019,30(1):143-156.e5. DOI：10.1016/j.cmet.2019.04.002.
[62]	KANG X, ZHANG R, KWONG T N，et al. Serrated neoplasia in the colorectum：gut microbiota and molecular pathways[J]. Gut Microbes，2021,13(1):1-12. DOI：10.1080/19490976.2020.1863135.

血脂异常与结直肠锯齿状病变、结直肠癌相关性研究进展

Research Progress on the Correlation of Dyslipidemia with Colorectal Serrated Lesions and Colorectal Cancer

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 62

相关文章 15

编辑推荐

Metrics

留言

[1]	冯宇茜, 王津津, 蔡一, 朱润芝, 朱勤. 乳酸化修饰在肾脏疾病中的研究进展[J]. 中国全科医学, 2026, 29(21): 3056-3063.
[2]	李文萍, 陈建华, 许家培, 金雪, 潘子涵, 迟春花. 数智化健康管理平台赋能社区老年人健康服务的范围综述[J]. 中国全科医学, 2026, 29(21): 2938-2949.
[3]	程玉, 韩士尧, 孙平, 向娟, 杨辉, 李东泽, 郑莉, 廖晓阳. 慢性病管理中的社会经济与人口学挑战分析[J]. 中国全科医学, 2026, 29(20): 2800-2807.
[4]	陈义萍, 张剑梅, 厉彦虎, 李睿, 张瑞平, 杨萍. COVID-19后遗症心肌损伤的诊疗进展[J]. 中国全科医学, 2026, 29(18): 2585-2592.
[5]	张明悦, 侯艳. 呼出气、肺泡气一氧化氮在间质性肺疾病中的研究进展[J]. 中国全科医学, 2026, 29(18): 2571-2576.
[6]	苗境杰, 张晋雯, 吴千豪, 韩佩佩. 间歇性禁食对心血管代谢疾病影响的研究进展[J]. 中国全科医学, 2026, 29(18): 2538-2545.
[7]	刘岱岳, 刘新灿, 兰真真. 餐后高脂血症及其治疗的研究进展[J]. 中国全科医学, 2026, 29(18): 2546-2553.
[8]	马晓雨, 马晓梅, 武国智, 郑亚, 郭庆红. 中性粒细胞外陷阱在胃癌中的研究进展[J]. 中国全科医学, 2026, 29(17): 2425-2432.
[9]	李佳威, 葛奥淇, 高欣怡, 李娟娟, 袁蓓蓓. 医防融合的概念内涵和实现路径：一项系统综述研究[J]. 中国全科医学, 2026, 29(16): 2156-2166.
[10]	汪洋, 金花, 杨森, 杨辉, 于德华. 中国基本医疗服务功能特征及其对卫生服务结局的影响路径：一项15年的混合方法系统综述[J]. 中国全科医学, 2026, 29(16): 2140-2155.
[11]	徐萍, 马艳, 黄莉, 何梅亮, 侯云凤, 王德旺, 孙盼盼, 刘峥, 郭艳芳, 徐英. 社区成年人体重调整腰围指数与高血压、糖尿病和血脂异常共病的关联研究[J]. 中国全科医学, 2026, 29(16): 2198-2204.
[12]	刘紫阳, 金梦龙, 刘森, 魏梦伟, 苏比努尔·居热提, 付真彦. 新疆维吾尔自治区不同民族接受PCSK9抑制剂治疗后的血脂水平差异研究[J]. 中国全科医学, 2026, 29(12): 1579-1587.
[13]	叶鑫瑛, 殷安康, 刘定岭, 吕翔, 王逸. 按病种分值付费支付模式下综合医院全科医学科发展研究[J]. 中国全科医学, 2026, 29(11): 1378-1384.
[14]	施雨峰, 卢晨霞, 吕安淇, 李晓东. 基于肠-肝轴理论探讨韦荣球菌属与肝脏疾病关系的研究进展[J]. 中国全科医学, 2026, 29(11): 1488-1496.
[15]	孙宇辰, 石雅馨, 师伟. 经血源性干细胞联合补肾活血类中药治疗子宫内膜功能减退类疾病的研究进展[J]. 中国全科医学, 2026, 29(11): 1481-1487.